The 2025 GLP-1 guidelines have positioned these drugs at the forefront of type 2 diabetes management, reflecting their multifaceted benefits
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and/or heartburn
This has led to the development of Ex-4 as a hypoglycemic drug
Some experiments reported altered tyrosinase activity, pigmentation-related signalling or cell proliferation under specific laboratory conditions
GLP-1 aftercare and metabolic continuity services become more effective when maintenance coaching begins before routine support ends